Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of an authorized generic of Actos (pioglitazone-hydrochloride tablets) 15, 30 and 45mg.
Actos is marketed by Takeda Pharmaceuticals U.S.A., Inc. and used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes.
The brand product had annual sales of approximately $2.7 billion in the United States, based on IMS sales data as of June 30, 2012.
For comments and feedback: editorial@rttnews.com